Topical GHK-Cu: what skin studies tested and how to read the label

Topical GHK-Cu might improve how skin looks, and the proof is weak. A cream or serum is the legal, cosmetic form of a peptide that is otherwise sold as an unapproved injectable, and this is a different regulatory case from the vial: a serum sold to improve appearance needs no FDA approval as long as it makes no drug claims. FDA has not approved GHK-Cu as a drug for any use. Vials sold for research use only are not legal to use on people, and none of the studies below tested one.

What the topical studies tested

How to read this table

• Small and short. A 2026 systematic review says most human GHK-Cu studies enrolled fewer than 100 people and ran 8 to 16 weeks. Another 2026 review in Aesthetic Surgery Journal found 20 eligible studies, of which only 2 were randomized controlled trials.
• Abstracts, not papers. The Leyden facial and eye-cream studies and the Abdulghani biopsy study, which supply most cosmetic marketing claims, were published only as conference abstracts. They have never been peer reviewed in full, and reviews cannot even agree on how long one of them ran.
• Hard outcomes are mixed. Of the two wound trials, one was negative and one positive. The only randomized cosmetic trial with blinded measurement, after laser resurfacing, found no objective difference.
• Who wrote it. The same 2026 review found that about 35% of the primary GHK-Cu literature it covered included the researcher who first isolated the peptide or a colleague, both affiliated with a company that sells copper peptide products.
• Product chemistry. A 2026 review in Pharmaceutics points out that most papers treat GHK-Cu as one fixed ingredient, when its form can change with the formula. Two products with the same label name may not deliver the same thing.

Does topical GHK-Cu get through the skin?

Not easily. GHK-Cu is water-loving and charged, and lab studies show poor passage through intact skin. In one, no peptide crossed untreated human skin in nine hours, while microneedle-treated skin let 134 nanomoles of peptide through. A serum works, if it works, in the outer layers, and that is also why its results say nothing about an injection.

For the bigger picture on skin peptides see peptides for skin, and for percentages and arithmetic see the GHK-Cu dosage page.

How long does topical GHK-Cu take to work?

Nobody has measured the time to a visible result. The studies above checked skin at set points, usually at 8 to 16 weeks, so a reasonable test of any serum takes months. If you start a serum in March, a fair check is around June, and photos in the same light will tell you more than memory. One caution from the acne-scar study: an early gain had disappeared by week 16.

How to read a serum label

Position on the list. US rules require cosmetic ingredients in descending order of amount, but anything at 1% or less may be listed in any order after the ingredients above 1%. Published GHK-Cu studies used roughly 0.05% to 2%, so where copper tripeptide-1 sits near the end of a list says little about how much is there. Most labels do not state a percentage.

Claims on the box. FDA treats a product as a drug if it claims to treat disease or change the body’s structure or function. Its examples include claims to “regenerate cells” or “restore hair growth.” A cosmetic making such claims is being sold as an unapproved drug, whatever the ingredient.

Our walkthrough of copper peptide serums covers shopping for one in more detail.

Irritation and side effects

What is known is limited:

• A 2024 review stated that “no studies have been published on the possible side effects” of GHK-Cu or its palmitoyl form.
• A 2025 acne-scar study pairing microneedling with GHK-Cu serum flagged a risk of hyperpigmentation (skin darkening) in the GHK-Cu side, according to a 2026 review.
• A 2015 laboratory study found no clinically significant skin irritation in cell and pig skin models with microneedle delivery, according to a 2026 review.
• Copper is a recognized contact sensitizer in susceptible people, according to a 2026 review, and a penetration-enhancing product or broken skin raises exposure. Someone with a known copper or metal allergy has a reason for extra caution. A trial of GHK-Cu gel excludes people with a known copper or peptide sensitivity.
• Wilson disease is an inherited condition in which copper builds up in the body. No study has tested GHK-Cu in this group, so anyone with it should ask their specialist first.

Microneedling, dermarollers and other devices change the picture, because they open channels through the skin barrier that lab studies show GHK-Cu otherwise struggles to cross. That raises exposure, and no published human trial has tested GHK-Cu delivered by microneedle arrays.

A burning feeling that does not settle, spreading redness, swelling or a rash is a reason to stop and show the ingredient list to a pharmacist or dermatologist. Trouble breathing or swelling of the face or throat after any product is an emergency.

Combining with other actives

The sourced information is thin:

• Hyaluronic acid. In a lab study, GHK-Cu combined with low-molecular-weight hyaluronic acid at a 1 to 9 ratio raised collagen IV production in skin cells and in skin samples. This was not a clinical trial.
• Microneedling. Small studies have paired GHK-Cu serum with dermarollers for acne scars, with mixed results, as in the table above.
• Oxidizing conditions. In stability tests, an oxidizing solution (0.5% hydrogen peroxide) was the harshest stress: only 84.2% of GHK-Cu remained after one hour. Solutions at pH 5.5 and 7.4 showed no detectable breakdown at 60 °C over 14 days.
• Vitamin C, retinoids and acids. One early study compared GHK-Cu with vitamin C and tretinoin creams in separate groups of people, but we found no published study testing them combined, for benefit or for safety. A 2026 review notes that reducing agents and antioxidants shift copper’s chemical state and that chelators such as citrate compete with GHK for copper, so a formula can change what the copper is doing. Whether that matters on skin has not been tested.

The line between cosmetic and drug

Topical GHK-Cu sold to improve appearance is a cosmetic. That does not put it outside regulation: under the 2022 cosmetics law, the company must keep records supporting the product’s safety, report serious adverse events to FDA within 15 business days and register its manufacturing facilities, and FDA can order a recall in serious cases. FDA does not check that a serum works before it goes on sale.

Non-injectable GHK-Cu is also in 503A category 1 on FDA’s May 14, 2026 list, so a pharmacy may compound a prescription cream under FDA’s interim policy. Injectable GHK-Cu is not approved, has no compounding route, and has never been tested in a human trial. GHK-Cu is not on the list in the October 2026 HHS peptide policy, so as of November 2, 2026 its status is unchanged. The topical studies say nothing about injection, and the FDA status tracker shows where each form stands.